TABLE 4.
Tazobactam final irreducible model parameters, bootstrap results, and DBS estimatesa
| Parameter | Point estimate | % RSE | Bootstrap CI |
Point estimate with DBS | ||
|---|---|---|---|---|---|---|
| 2.5% | Median | 97.5% | ||||
| Typical CL value (liters/kg/h) | 0.088 | 8.9 | 0.072 | 0.088 | 0.105 | 0.085 |
| Typical V value (liters/kg) | 0.57 | 5.4 | 0.52 | 0.57 | 0.64 | 0.59 |
| PMA covariate | 1.35 | 27.3 | 0.53 | 1.32 | 2.31 | 1.47 |
| SCR covariate | −0.35 | 37.0 | −0.70 | −0.35 | −0.07 | −0.31 |
| GENT covariate | 1.52 | 10.1 | 1.26 | 1.53 | 1.91 | 1.56 |
| DBS matrix factor | 0.48 | |||||
| CL interindividual variability (CV [%]) | 23 | 34.0 | 12 | 21 | 30 | 24 |
| Proportional residual error (CV [%]) | 24 | 19.8 | 11 | 23 | 30 | 27 |
| Plasma additive residual error (mg/liter) | 1.43 | 51.2 | 11.0 | 22.7 | 30.2 | 1.26 |
| DBS additive residual error (mg/liter) | NA | NA | NA | NA | NA | 0.13 |
a
GENT is concurrent gentamicin administration (GENT = 1). Abbreviations are as defined in footnote a of Table 3.